Related Experiment Video
Updated: May 16, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization
Chen Xuan1,2, Donghui Chen2,3, Shuangna Zhang2
1School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Isoquercitrin effectively treats diabetic nephropathy by inhibiting signal transducer and activator of transcription 3 (STAT3). This natural compound, delivered via a novel nanocarrier, reduces kidney inflammation and fibrosis, offering a promising new therapy.
Area of Science:
- Biochemistry
- Pharmacology
- Nephrology
Background:
- Diabetic nephropathy (DN) presents a significant health challenge, with signal transducer and activator of transcription 3 (STAT3) emerging as a key therapeutic target.
- Isoquercitrin, a natural compound, is recognized for its potential to inhibit STAT3, but its precise mechanism in DN remains largely unexplored.
Purpose of the Study:
- To elucidate the therapeutic mechanism of isoquercitrin in diabetic nephropathy by investigating its interaction with STAT3.
- To develop and evaluate a novel kidney-targeted nanocarrier for enhanced delivery of isoquercitrin in DN treatment.
Main Methods:
- Investigated the effect of isoquercitrin on renal inflammation and fibrosis in a mouse model of diabetic nephropathy.
- Utilized biophysical techniques to confirm the direct binding of isoquercitrin to STAT3, specifically within the SH2 domain.
- Developed and characterized a kidney-targeted nanocarrier (Iso@PEG-GK) for isoquercitrin delivery.
Main Results:
- Isoquercitrin significantly reduced inflammation and fibrosis in mice with diabetic nephropathy by inhibiting STAT3 activity.
- Confirmed direct, noncovalent binding of isoquercitrin to the Ser668-Gln635-Gln633 region of the STAT3 SH2 domain, obstructing phosphorylation and dimerization.
- The Iso@PEG-GK nanocarrier demonstrated enhanced absorption and improved renal distribution of isoquercitrin, leading to superior therapeutic outcomes.
Conclusions:
- Isoquercitrin exerts a protective effect against diabetic nephropathy through direct inhibition of STAT3 signaling.
- The development of a kidney-targeted nanocarrier enhances the therapeutic potential of isoquercitrin for diabetic nephropathy.
- Isoquercitrin represents a promising novel therapeutic agent for managing diabetic nephropathy.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
The JAK-STAT Signaling Pathway
Dipeptidyl Peptidase 4 Inhibitors
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Insulin: The Receptor and Signaling Pathways
Antihypertensive Drugs: Direct Renin Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...